What is the role of rituximab in the treatment of immunoglobulin A (IgA) neuropathy?

Updated: May 19, 2020
  • Author: Sohail Abdul Salim, MD, FASN, FACP; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

CD19 B-cells are increased in IgA nephropathy. However, in a randomized controlled trial in 34 patients with proteinuria and renal dysfunction, treatment with rituximab did not significantly improve renal function or proteinuria over the course of 1 year.  Rituximab had no significant effect on GFR, proteinuria, galactose-deficient IgA1 levels, or IgG autoantibodies. Consequently, the authors do not recommend the use of rituximab in these patients. [42]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!